2023
Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity
Galderisi A, Tricò D, Lat J, Samuels S, Weiss R, Van Name M, Pierpont B, Santoro N, Caprio S. Incretin effect determines glucose trajectory and insulin sensitivity in youths with obesity. JCI Insight 2023, 8: e165709. PMID: 37847560, PMCID: PMC10721315, DOI: 10.1172/jci.insight.165709.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseDiabetes Mellitus, Type 2GlucoseHumansIncretinsInsulinInsulin ResistanceObesityConceptsOral glucose tolerance testΒ-cell functionIncretin effectBeta-cell functionInsulin sensitivityInsulin secretionGlucose levelsCell functionIsoglycemic intravenous glucose infusionGreater insulin sensitivityIntravenous glucose infusionPubertal transitionGlucose tolerance testGLP-17Glucagon suppressionGlucose infusionObesityLongitudinal increaseBaselineOGTTEffect groupGreater increaseLongitudinal trajectoriesSecretionGroup
2022
Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications
Shah R, Chernausek S, ghormli L, Geffner M, Keady J, Kelsey M, Farrell R, Tesfaldet B, Tryggestad J, Van Name M, Isganaitis E. Maternal Diabetes in Youth-Onset Type 2 Diabetes Is Associated With Progressive Dysglycemia and Risk of Complications. The Journal Of Clinical Endocrinology & Metabolism 2022, 108: 1120-1131. PMID: 36446741, PMCID: PMC10306086, DOI: 10.1210/clinem/dgac663.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentDiabetes Mellitus, Type 2Diabetes, GestationalFemaleFollow-Up StudiesGlycated HemoglobinHumansMalePregnancyRisk FactorsConceptsYouth-onset type 2 diabetesType 2 diabetesMaternal diabetesHeart rate variabilityGlomerular hyperfiltrationParental diabetesGlycemic controlRate variabilityFuture cardiometabolic diseaseParental diabetes historyYouth-onset T2D.Lower heart rate variabilityRisk of complicationsWorse glycemic controlΒ-cell functionRace/ethnicityDiabetes historyCardiometabolic diseasesDiabetes outcomesPrenatal exposureUS cohortGlycemic outcomesRisk factorsDisease progressionUS CentersWhen insulin isn’t enough: targeting glucagon in type 1 diabetes
Van Name M, Sherr J. When insulin isn’t enough: targeting glucagon in type 1 diabetes. Nature Medicine 2022, 28: 2007-2008. PMID: 36192555, DOI: 10.1038/s41591-022-02019-3.Commentaries, Editorials and LettersEfficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study
Tamborlane WV, Laffel LM, Shehadeh N, Isganaitis E, Van Name M, Ratnayake J, Karlsson C, Norjavaara E. Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. The Lancet Diabetes & Endocrinology 2022, 10: 341-350. PMID: 35378069, PMCID: PMC10851108, DOI: 10.1016/s2213-8587(22)00052-3.Peer-Reviewed Original ResearchConceptsType 2 diabetesPlacebo-assigned participantsPrespecified sensitivity analysisSafety of dapagliflozinPhase 3 studyBetween-group differencesAdverse eventsPrimary outcomeProtocol populationTreat analysisYoung adultsWeek double-blind periodRandomised phase 3 studyDouble-blind periodSerious adverse eventsNew safety signalsOral dapagliflozinDiabetic ketoacidosisSevere hypoglycaemiaMean ageTreatment optionsCare treatmentParallel groupSafety signalsStudy personnelYouth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study
Wolf RM, Cheng P, Gal RL, Beaulieu LC, Kollman C, Isganaitis E, Magge S, Mastrandrea LD, Klingensmith GJ, Tamborlane W, Van Name M, Consortium P. Youth with type 2 diabetes have a high rate of treatment failure after discontinuation of insulin: A Pediatric Diabetes Consortium study. Pediatric Diabetes 2022, 23: 439-446. PMID: 35138021, DOI: 10.1111/pedi.13325.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentBlood GlucoseDiabetes Mellitus, Type 2Glycated HemoglobinHumansHypoglycemic AgentsInsulinMetforminTreatment FailureConceptsIntensive lifestyle interventionTreatment failureType 2 diabetesDiabetes medicationsLifestyle interventionGlycemic controlDiscontinuation of insulinExperienced treatment failureInitial insulin treatmentYouth-onset T2DHigh rateMetformin monotherapyPrimary outcomeMedian timeRisk factorsInsulin treatmentMetforminProgressive natureConsortium studyLogistic regressionInsulinT2DIntensive lifestyleMedicationsDiabetes
2021
Long-Term Complications in Youth-Onset Type 2 Diabetes
Bjornstad P, Drews K, Caprio S, Gubitosi-Klug R, Nathan D, Tesfaldet B, Tryggestad J, White N, Zeitler P. Long-Term Complications in Youth-Onset Type 2 Diabetes. New England Journal Of Medicine 2021, 385: 416-426. PMID: 34320286, PMCID: PMC8697255, DOI: 10.1056/nejmoa2100165.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentChildDiabetes ComplicationsDiabetes Mellitus, Type 2DyslipidemiasFemaleFollow-Up StudiesHumansHypertensionHypoglycemic AgentsMaleMetforminRisk FactorsConceptsType 2 diabetesDiabetic kidney diseaseNerve diseaseKidney diseaseRetinal diseasesYouth-Onset Type 2Minority raceDevelopment of complicationsIncidence of dyslipidemiaRisk of complicationsMulticenter clinical trialDiagnosis of diabetesMicrovascular complicationsAdverse eventsCumulative incidenceTerm complicationsGlycemic controlRelated complicationsObservational followMean ageRisk factorsClinical trialsComplicationsDyslipidemiaHypertension
2020
Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study
Weinstock R, Braffett B, Songer T, Herman W, Kuo S, Gubitosi-Klug R, Laffel L, McKay S, Siska M, Van Name M, Zeitler P. Health Care Coverage and Glycemic Control in Young Adults With Youth-Onset Type 2 Diabetes: Results From the TODAY2 Study. Diabetes Care 2020, 43: 2469-2477. PMID: 32778555, PMCID: PMC7510035, DOI: 10.2337/dc20-0760.Peer-Reviewed Original ResearchConceptsType 2 diabetesHealth care coverageCare coverageGlycemic controlYoung adultsYouth-onset type 2 diabetesCommunity careYouth-Onset Type 2Medicaid expansionCommercial coverageCommunity diabetes careGovernment coverageDiabetes careDiabetes visitsTreatment optionsMore young adultsNew therapiesType 2DiabetesTODAY cohortCentral laboratoryVulnerable populationsCareCommercial plansHbATransforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model
Van Name M, Klingensmith G, Nelson B, Wintergerst K, Mitchell J, Norris K, Tamborlane W, Clements M, Hannon T, Shoemaker A, Wood J, Gal R. Transforming Performance of Clinical Trials in Pediatric Type 2 Diabetes: A Consortium Model. Diabetes Technology & Therapeutics 2020, 22: 330-336. PMID: 31859529, PMCID: PMC7869879, DOI: 10.1089/dia.2019.0448.Peer-Reviewed Original ResearchMeSH KeywordsBiomedical ResearchChildClinical Trials, Phase III as TopicCooperative BehaviorDiabetes Mellitus, Type 2FemaleHumansMaleModels, OrganizationalResearch DesignConceptsPediatric Diabetes ConsortiumType 2 diabetesClinical centersCoordinating CenterPediatric treatment centerPediatric type 1 diabetesPhase 3 trialType 2 Diabetes StudyType 1 diabetesPediatric Type 2Diabetes-related studiesTreatment of youthPivotal trialsRandomized subjectsDiabetes StudyStudy protocolClinical trialsContract research organizationsConsortium modelTreatment centersType 2DiabetesNew drugsTrialsEnrollment strategiesChildren and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control
Van Name MA, Cheng P, Gal RL, Kollman C, Lynch J, Nelson B, Tamborlane WV, Consortium F. Children and adolescents with type 1 and type 2 diabetes mellitus in the Pediatric Diabetes Consortium Registries: comparing clinical characteristics and glycaemic control. Diabetic Medicine 2020, 37: 863-867. PMID: 31943374, DOI: 10.1111/dme.14233.Peer-Reviewed Original ResearchConceptsType 2 diabetesType 1 diabetesPediatric Diabetes ConsortiumTarget HbAType 1Median C-peptide levelsResidual endogenous insulin secretionType 2 diabetes mellitusC-peptide levelsEndogenous insulin secretionOverweight/obeseYears of agePoor diabetes outcomesSubset of participantsCharacteristics of childrenDiabetic ketoacidosisGlycaemic controlClinical characteristicsDiabetes mellitusDiabetes outcomesRisk factorsFamilies of childrenInsulin secretionInsulin treatmentDiabetes diagnosis
2019
Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice
Elahi S, Patel AD, Guandalini C, Steffen A, Sherr J, Tamborlane WV, Van Name MA. Impact of Switching Youth With Diabetes to Insulin Degludec in Clinical Practice. Endocrine Practice 2019, 25: 226-229. PMID: 30913005, DOI: 10.4158/ep-2018-0417.Peer-Reviewed Original ResearchMeSH KeywordsDiabetes Mellitus, Type 2Glycated HemoglobinHumansHypoglycemiaHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingProspective StudiesRetrospective StudiesConceptsType 1 diabetesInsulin degludecDiabetic ketoacidosisGlycemic controlCurrent regimenPatient's current regimenRetrospective chart reviewMonths of treatmentBeta-cell functionType 2 diabetesDiabetes-PatientenUltralong durationChart reviewGlycemic targetsBasal insulinHemoglobin A1cGlycemic outcomesMissed dosesOutcome differencesIDegClinical practiceDiabetes struggleDiabetesType 2Degludec
2018
Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry
Tamborlane WV, Chang P, Kollman C, Klingensmith GJ, Ruedy K, Gal RL, Van Name M, Bacha F, Willi S, Beck RW, Consortium F. Eligibility for clinical trials is limited for youth with type 2 diabetes: Insights from the Pediatric Diabetes Consortium T2D Clinic Registry. Pediatric Diabetes 2018, 19: 1379-1384. PMID: 30175440, DOI: 10.1111/pedi.12763.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge of OnsetChildClinical Trials as TopicDiabetes Mellitus, Type 2FemaleHealth Services AccessibilityHumansMalePatient SelectionPediatricsRegistriesResearch DesignConceptsType 2 diabetesT2D durationT2D patientsClinical trialsEligibility criteriaPlacebo-assigned subjectsPercentage of patientsCurrent clinical trialsRestrictive eligibility criteriaBaseline HbA1cHbA1c levelsClinical characteristicsClinic registryRegistry enrollmentInvestigational treatmentPatientsCurrent trialTrialsNew drugsMonthsHbA1cRatio of femaleDiabetesRegistryEnrollmentThe present and future treatment of pediatric type 2 diabetes
Van Name MA, Guandalini C, Steffen A, Patel A, Tamborlane W. The present and future treatment of pediatric type 2 diabetes. Expert Review Of Endocrinology & Metabolism 2018, 13: 207-212. PMID: 30063424, DOI: 10.1080/17446651.2018.1499467.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsType 2 diabetesPediatric type 2 diabetesStandard initial treatmentMetformin monotherapyPediatric T2DClinical outcomesInitial treatmentPediatric populationClinical trialsRapid progressionInjectable agentsFuture treatmentMetabolic controlT2DDiabetesNew drugsInsulinPhase 3DrugsRegulatory approvalT2D.TreatmentPatientsMetforminCurrent use
2016
Effective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting
Van Name MA, Camp AW, Magenheimer EA, Li F, Dziura JD, Montosa A, Patel A, Tamborlane WV. Effective Translation of an Intensive Lifestyle Intervention for Hispanic Women With Prediabetes in a Community Health Center Setting. Diabetes Care 2016, 39: 525-531. PMID: 26908915, PMCID: PMC4806769, DOI: 10.2337/dc15-1899.Peer-Reviewed Original ResearchMeSH KeywordsAdiposityAdolescentAdultAgedBody Mass IndexChoice BehaviorCommunity Health CentersDiabetes Mellitus, Type 2ExerciseFeasibility StudiesFemaleFood PreferencesHispanic or LatinoHumansInsulinLife StyleMiddle AgedPilot ProjectsPrediabetic StateRisk FactorsSocioeconomic FactorsWaist CircumferenceWeight LossYoung AdultConceptsIntensive lifestyle interventionDiabetes Prevention ProgramCommunity health center settingUsual care groupType 2 diabetesHealth center settingHispanic womenILI groupLifestyle interventionCare groupOral glucose tolerance testCenter settingLow-income Hispanic womenWeight lossSimilar baseline weightGlucose tolerance testPercent body fatType of interventionCHC settingsDPP interventionsUsual careBaseline weightWaist circumferenceGlucose excursionsTolerance test
2014
Can we get it right for youth with type 2 diabetes?
Tamborlane WV, Ruedy K, Van Name M, Klingensmith GJ. Can we get it right for youth with type 2 diabetes? Diabetes Research And Clinical Practice 2014, 106: 643-644. PMID: 25488379, DOI: 10.1016/j.diabres.2014.11.003.Peer-Reviewed Original Research